Healthcare
Live Price
Offline$15.63
+1.36% today
1Y Change
+3.43%
Window
Jun 23, 2025 → Jun 1, 2026
Coverage: 237 bars · Jun 23, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Takeda Pharmaceutical Company Limited (TAK) is a Healthcare stock with a market cap of $8.28T and listed on NYSE. The stock last traded around $15.63 and up 3.4% across the available one-year price window (Jun 23, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +7.5%, EPS growth of -25.8%, a dividend yield of 3.8%. What stands out right now is revenue +7.5%, EPS -25.8%, free cash flow +263.5% with operating margin 10.3% and ROIC 1.9%. The dividend matters to the case here, with a current yield around 3.8%. Valuation already assumes a fairly strong business story at P/E 73.3 and price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TAK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TAK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TAK Max Drawdown
-19.02%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TAK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.2T
-10.4% YoY
FY Net Income
$376.0B
+63.4% YoY
Free Cash Flow
$774.5B
-17.4% YoY
Revenue Growth
+7.5%
EPS Growth
-25.8%
Gross Margin
59.5%
Net Margin
2.5%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4581.6B | 4263.8B | 4027.5B | 3569.0B | 3197.8B |
| Gross Profit | 3001.3B | 2832.3B | 2783.4B | 2462.2B | 2203.5B |
| Operating Income | 342.6B | 214.1B | 490.5B | 460.8B | 509.3B |
| EBITDA | 1210.5B | 1143.9B | 1284.1B | 1183.2B | 983.7B |
| Net Income | 107.9B | 144.1B | 317.0B | 230.1B | 376.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 385.1B | 457.8B | 533.5B | 849.7B | 966.2B |
| Total Assets | 14248.3B | 15108.8B | 13957.8B | 13178.0B | 12912.3B |
| Total Liabilities | 7312.4B | 7834.8B | 7603.1B | 7494.5B | 7735.1B |
| Shareholder Equity | 6935.1B | 7273.3B | 6354.1B | 5683.0B | 5173.0B |
| Total Debt | 4515.3B | 4843.8B | 4382.3B | 4345.4B | 4635.4B |
| Net Debt | 4130.2B | 4386.0B | 3848.8B | 3495.7B | 3669.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1010.9B
-10.0% YoY
Capital Expenditures
236.5B
-27.1% YoY
Free Cash Flow
774.5B
-17.4% YoY
Key ratios
Gross Margin
59.5%
Operating Margin
10.3%
Net Margin
2.5%
ROE
1.6%
Debt / Equity
0.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.